In recent days, Leidos Holdings has been highlighted for QTC Health Services’ use of mobile clinics, AI-enabled tools, and telehealth to extend healthcare access to rural U.S. communities, while investors also await an earnings report with an expected EPS of $2.94, slightly lower than the same quarter last year.
At the same time, Leidos’ growing contract backlog, efficiency gains, share repurchases, and inclusion in the new Tuttle Capital UFO Disclosure ETF are underscoring its role at the intersection of defense technology, advanced digital solutions, and long-term government-funded projects.
Against this backdrop, we’ll explore how Leidos’ expanding backlog and AI-enabled health and defense solutions influence its existing investment narrative.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
To own Leidos, you generally need to believe in long-term, government-backed demand for defense, cyber, and health technology, with earnings supported by a growing contract backlog and efficiency gains. The latest rural health and AI news reinforces the breadth of its federal health footprint, but the key short term catalyst remains the upcoming earnings report, while dependence on U.S. government budgets is still the central risk and is not materially altered by this development.
The recent expansion of Leidos’ revolving credit facility to US$1.5 billion, alongside ongoing share repurchases, stands out in the context of its inclusion in the Tuttle Capital UFO Disclosure ETF. Together, these moves highlight how management is positioning the balance sheet and capital returns around a business built on long duration, government-funded technology programs, even as investors weigh shorter term earnings volatility and policy risk.
Yet behind the attractive backlog and AI story, investors should be aware of how concentrated Leidos still is in U.S. federal funding and…
Read the full narrative on Leidos Holdings (it’s free!)
Leidos Holdings’ narrative projects $18.6 billion revenue and $1.5 billion earnings by 2028.
Uncover how Leidos Holdings’ forecasts yield a $212.46 fair value, a 34% upside to its current price.
LDOS 1-Year Stock Price Chart
Four fair value estimates from the Simply Wall St Community span roughly US$212 to US$290 per share, showing how widely private investors can differ. You can weigh these views against the central risk that shifts in U.S. government priorities could affect Leidos’ large, multi year contract base and, in turn, its longer term performance.
Explore 4 other fair value estimates on Leidos Holdings – why the stock might be worth as much as 82% more than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LDOS.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com